+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Global Oncolytic Virus Therapies Market by Virus Type (Genetically Engineered Oncolytic Viruses, Oncolytic Wild-type Viruses), Application (Breast Cancer, Lung Cancer, Melanoma), End Use - Forecast 2024-2030- Product Image
Global Oncolytic Virus Therapies Market by Virus Type (Genetically Engineered Oncolytic Viruses, Oncolytic Wild-type Viruses), Application (Breast Cancer, Lung Cancer, Melanoma), End Use - Forecast 2024-2030- Product Image
Sale

Global Oncolytic Virus Therapies Market by Virus Type (Genetically Engineered Oncolytic Viruses, Oncolytic Wild-type Viruses), Application (Breast Cancer, Lung Cancer, Melanoma), End Use - Forecast 2024-2030

  • PDF Icon

    Report

  • 189 Pages
  • March 2024
  • Region: Global
  • 360iResearch™
  • ID: 5925124
UP TO OFF until Dec 31st 2024
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Oncolytic Virus Therapies Market size was estimated at USD 117.53 million in 2023, USD 132.50 million in 2024, and is expected to grow at a CAGR of 15.45% to reach USD 321.30 million by 2030.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Oncolytic Virus Therapies Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Oncolytic Virus Therapies Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Oncolytic Virus Therapies Market, highlighting leading vendors and their innovative profiles. These include Amunbio Inc., Astellas Pharma Inc., AstraZeneca PLC, BioInvent International AB, Boehringer Ingelheim International GmbH, Calidi Biotherapeutics, Inc., Candel Therapeutics, Daiichi Sankyo Company Ltd., Elicera Therapeutics AB, EpicentRx, Inc., Genelux Corporation, Hookipa Pharma Inc., Imvaq Therapeutics, Istari Oncology, Inc., Johnson & Johnson Services, Inc., Lokon Pharma AB, Merck & Co., Inc., Orgenesis Inc., Pfizer, Inc., Protheragen Inc., Seneca Therapeutics, Inc., Takara Bio Inc., TILT Biotherapeutics, Treovir LLC, and Wuhan Binhui Biotechnology Co Ltd.

Market Segmentation & Coverage

This research report categorizes the Oncolytic Virus Therapies Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Virus Type
    • Genetically Engineered Oncolytic Viruses
    • Oncolytic Wild-type Viruses
  • Application
    • Breast Cancer
    • Lung Cancer
    • Melanoma
    • Ovarian Cancer
    • Prostate Cancer
  • End Use
    • Cancer Research Institutes
    • Hospitals
    • Specialty Clinics
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

  1. Market Penetration: It presents comprehensive information on the market provided by key players.
  2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
  3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
  4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
  5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

  1. What is the market size and forecast of the Oncolytic Virus Therapies Market?
  2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Oncolytic Virus Therapies Market?
  3. What are the technology trends and regulatory frameworks in the Oncolytic Virus Therapies Market?
  4. What is the market share of the leading vendors in the Oncolytic Virus Therapies Market?
  5. Which modes and strategic moves are suitable for entering the Oncolytic Virus Therapies Market?

With the purchase of this report at the Multi-user License or greater level, you will have access to one hour with an expert analyst who will help you link key findings in the report to the business issues you're addressing. This will need to be used within three months of purchase.

This report also includes a complimentary Excel file with data from the report for purchasers at the Site License or greater level.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders

2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview
4.1. Introduction
4.2. Oncolytic Virus Therapies Market, by Region

5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Rising incidence of cancer among the global population
5.1.1.2. Awareness program to promote immunotherapy
5.1.2. Restraints
5.1.2.1. Risk and complication associated with oncolytic virus therapies
5.1.3. Opportunities
5.1.3.1. Ongoing R&D to develop advanced oncolytic virus therapies
5.1.3.2. Rise of oncolytic virus therapies as a precision medicine strategy
5.1.4. Challenges
5.1.4.1. Complex regulatory framework surrounding oncolytic virus therapy
5.2. Market Segmentation Analysis
5.3. Market Trend Analysis
5.4. Cumulative Impact of High Inflation
5.5. Porter’s Five Forces Analysis
5.5.1. Threat of New Entrants
5.5.2. Threat of Substitutes
5.5.3. Bargaining Power of Customers
5.5.4. Bargaining Power of Suppliers
5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework

6. Oncolytic Virus Therapies Market, by Virus Type
6.1. Introduction
6.2. Genetically Engineered Oncolytic Viruses
6.3. Oncolytic Wild-type Viruses

7. Oncolytic Virus Therapies Market, by Application
7.1. Introduction
7.2. Breast Cancer
7.3. Lung Cancer
7.4. Melanoma
7.5. Ovarian Cancer
7.6. Prostate Cancer

8. Oncolytic Virus Therapies Market, by End Use
8.1. Introduction
8.2. Cancer Research Institutes
8.3. Hospitals
8.4. Specialty Clinics

9. Americas Oncolytic Virus Therapies Market
9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States

10. Asia-Pacific Oncolytic Virus Therapies Market
10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam

11. Europe, Middle East & Africa Oncolytic Virus Therapies Market
11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom

12. Competitive Landscape
12.1. FPNV Positioning Matrix
12.2. Market Share Analysis, By Key Player
12.3. Competitive Scenario Analysis, By Key Player

13. Competitive Portfolio
13.1. Key Company Profiles
13.1.1. Amunbio Inc.
13.1.2. Astellas Pharma Inc.
13.1.3. AstraZeneca PLC
13.1.4. BioInvent International AB
13.1.5. Boehringer Ingelheim International GmbH
13.1.6. Calidi Biotherapeutics, Inc.
13.1.7. Candel Therapeutics
13.1.8. Daiichi Sankyo Company Ltd.
13.1.9. Elicera Therapeutics AB
13.1.10. EpicentRx, Inc.
13.1.11. Genelux Corporation
13.1.12. Hookipa Pharma Inc.
13.1.13. Imvaq Therapeutics
13.1.14. Istari Oncology, Inc.
13.1.15. Johnson & Johnson Services, Inc.
13.1.16. Lokon Pharma AB
13.1.17. Merck & Co., Inc.
13.1.18. Orgenesis Inc.
13.1.19. Pfizer, Inc.
13.1.20. Protheragen Inc.
13.1.21. Seneca Therapeutics, Inc.
13.1.22. Takara Bio Inc.
13.1.23. TILT Biotherapeutics
13.1.24. Treovir LLC
13.1.25. Wuhan Binhui Biotechnology Co Ltd
13.2. Key Product Portfolio

14. Appendix
14.1. Discussion Guide
14.2. License & Pricing

List of Figures
FIGURE 1. ONCOLYTIC VIRUS THERAPIES MARKET RESEARCH PROCESS
FIGURE 2. ONCOLYTIC VIRUS THERAPIES MARKET SIZE, 2023 VS 2030
FIGURE 3. ONCOLYTIC VIRUS THERAPIES MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY REGION, 2023 VS 2030 (%)
FIGURE 5. ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. ONCOLYTIC VIRUS THERAPIES MARKET DYNAMICS
FIGURE 7. ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2023 VS 2030 (%)
FIGURE 8. ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 9. ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
FIGURE 10. ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 11. ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USE, 2023 VS 2030 (%)
FIGURE 12. ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 13. AMERICAS ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 14. AMERICAS ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 15. UNITED STATES ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 16. UNITED STATES ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 17. ASIA-PACIFIC ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 18. ASIA-PACIFIC ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 21. ONCOLYTIC VIRUS THERAPIES MARKET, FPNV POSITIONING MATRIX, 2023
FIGURE 22. ONCOLYTIC VIRUS THERAPIES MARKET SHARE, BY KEY PLAYER, 2023


List of Tables
TABLE 1. ONCOLYTIC VIRUS THERAPIES MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. ONCOLYTIC VIRUS THERAPIES MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2030 (USD MILLION)
TABLE 6. ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY GENETICALLY ENGINEERED ONCOLYTIC VIRUSES, BY REGION, 2018-2030 (USD MILLION)
TABLE 7. ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY ONCOLYTIC WILD-TYPE VIRUSES, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 9. ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY MELANOMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY OVARIAN CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 15. ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY CANCER RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. AMERICAS ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2030 (USD MILLION)
TABLE 19. AMERICAS ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 20. AMERICAS ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 21. AMERICAS ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 22. ARGENTINA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2030 (USD MILLION)
TABLE 23. ARGENTINA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 24. ARGENTINA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 25. BRAZIL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2030 (USD MILLION)
TABLE 26. BRAZIL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 27. BRAZIL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 28. CANADA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2030 (USD MILLION)
TABLE 29. CANADA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 30. CANADA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 31. MEXICO ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2030 (USD MILLION)
TABLE 32. MEXICO ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 33. MEXICO ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 34. UNITED STATES ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2030 (USD MILLION)
TABLE 35. UNITED STATES ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 36. UNITED STATES ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 37. UNITED STATES ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 38. ASIA-PACIFIC ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2030 (USD MILLION)
TABLE 39. ASIA-PACIFIC ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 40. ASIA-PACIFIC ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 41. ASIA-PACIFIC ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 42. AUSTRALIA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2030 (USD MILLION)
TABLE 43. AUSTRALIA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 44. AUSTRALIA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 45. CHINA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2030 (USD MILLION)
TABLE 46. CHINA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 47. CHINA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 48. INDIA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2030 (USD MILLION)
TABLE 49. INDIA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 50. INDIA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 51. INDONESIA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2030 (USD MILLION)
TABLE 52. INDONESIA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 53. INDONESIA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 54. JAPAN ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2030 (USD MILLION)
TABLE 55. JAPAN ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 56. JAPAN ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 57. MALAYSIA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2030 (USD MILLION)
TABLE 58. MALAYSIA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 59. MALAYSIA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 60. PHILIPPINES ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2030 (USD MILLION)
TABLE 61. PHILIPPINES ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 62. PHILIPPINES ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 63. SINGAPORE ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2030 (USD MILLION)
TABLE 64. SINGAPORE ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 65. SINGAPORE ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 66. SOUTH KOREA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2030 (USD MILLION)
TABLE 67. SOUTH KOREA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 68. SOUTH KOREA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 69. TAIWAN ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2030 (USD MILLION)
TABLE 70. TAIWAN ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 71. TAIWAN ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 72. THAILAND ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2030 (USD MILLION)
TABLE 73. THAILAND ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 74. THAILAND ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 75. VIETNAM ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2030 (USD MILLION)
TABLE 76. VIETNAM ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 77. VIETNAM ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 78. EUROPE, MIDDLE EAST & AFRICA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2030 (USD MILLION)
TABLE 79. EUROPE, MIDDLE EAST & AFRICA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 80. EUROPE, MIDDLE EAST & AFRICA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 81. EUROPE, MIDDLE EAST & AFRICA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 82. DENMARK ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2030 (USD MILLION)
TABLE 83. DENMARK ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 84. DENMARK ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 85. EGYPT ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2030 (USD MILLION)
TABLE 86. EGYPT ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 87. EGYPT ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 88. FINLAND ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2030 (USD MILLION)
TABLE 89. FINLAND ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 90. FINLAND ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 91. FRANCE ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2030 (USD MILLION)
TABLE 92. FRANCE ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 93. FRANCE ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 94. GERMANY ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2030 (USD MILLION)
TABLE 95. GERMANY ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 96. GERMANY ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 97. ISRAEL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2030 (USD MILLION)
TABLE 98. ISRAEL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 99. ISRAEL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 100. ITALY ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2030 (USD MILLION)
TABLE 101. ITALY ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 102. ITALY ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 103. NETHERLANDS ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2030 (USD MILLION)
TABLE 104. NETHERLANDS ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 105. NETHERLANDS ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 106. NIGERIA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2030 (USD MILLION)
TABLE 107. NIGERIA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 108. NIGERIA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 109. NORWAY ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2030 (USD MILLION)
TABLE 110. NORWAY ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 111. NORWAY ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 112. POLAND ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2030 (USD MILLION)
TABLE 113. POLAND ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 114. POLAND ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 115. QATAR ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2030 (USD MILLION)
TABLE 116. QATAR ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 117. QATAR ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 118. RUSSIA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2030 (USD MILLION)
TABLE 119. RUSSIA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 120. RUSSIA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 121. SAUDI ARABIA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2030 (USD MILLION)
TABLE 122. SAUDI ARABIA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 123. SAUDI ARABIA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 124. SOUTH AFRICA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2030 (USD MILLION)
TABLE 125. SOUTH AFRICA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 126. SOUTH AFRICA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 127. SPAIN ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2030 (USD MILLION)
TABLE 128. SPAIN ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 129. SPAIN ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 130. SWEDEN ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2030 (USD MILLION)
TABLE 131. SWEDEN ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 132. SWEDEN ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 133. SWITZERLAND ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2030 (USD MILLION)
TABLE 134. SWITZERLAND ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 135. SWITZERLAND ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 136. TURKEY ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2030 (USD MILLION)
TABLE 137. TURKEY ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 138. TURKEY ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 139. UNITED ARAB EMIRATES ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2030 (USD MILLION)
TABLE 140. UNITED ARAB EMIRATES ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 141. UNITED ARAB EMIRATES ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 142. UNITED KINGDOM ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2030 (USD MILLION)
TABLE 143. UNITED KINGDOM ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 144. UNITED KINGDOM ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 145. ONCOLYTIC VIRUS THERAPIES MARKET, FPNV POSITIONING MATRIX, 2023
TABLE 146. ONCOLYTIC VIRUS THERAPIES MARKET SHARE, BY KEY PLAYER, 2023
TABLE 147. ONCOLYTIC VIRUS THERAPIES MARKET LICENSE & PRICING

Companies Mentioned

  • Amunbio Inc.
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • BioInvent International AB
  • Boehringer Ingelheim International GmbH
  • Calidi Biotherapeutics, Inc.
  • Candel Therapeutics
  • Daiichi Sankyo Company Ltd.
  • Elicera Therapeutics AB
  • EpicentRx, Inc.
  • Genelux Corporation
  • Hookipa Pharma Inc.
  • Imvaq Therapeutics
  • Istari Oncology, Inc.
  • Johnson & Johnson Services, Inc.
  • Lokon Pharma AB
  • Merck & Co., Inc.
  • Orgenesis Inc.
  • Pfizer, Inc.
  • Protheragen Inc.
  • Seneca Therapeutics, Inc.
  • Takara Bio Inc.
  • TILT Biotherapeutics
  • Treovir LLC
  • Wuhan Binhui Biotechnology Co Ltd

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages189
PublishedMarch 2024
Forecast Period2024 - 2030
Estimated Market Value ( USD ) in 2024 $ 132.5 Million
Forecasted Market Value ( USD ) by 2030 $ 321.3 Million
Compound Annual Growth Rate15.4%
Regions CoveredGlobal
No. of Companies Mentioned25

Related Topics

Related Reports

Global Oncolytic Virus Therapy Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2023-2031 - Product Image

Global Oncolytic Virus Therapy Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2023-2031

  • Report
  • 112 Pages
  • Global
From
Oncolytic Virus Therapy Global Market Report 2024 - Product Image

Oncolytic Virus Therapy Global Market Report 2024

  • Report
  • 175 Pages
  • Global
From
Oncolytic Virus Therapy Global Market Insights 2023, Analysis and Forecast to 2028, by Manufacturers, Regions, Technology, Application, Product Type - Product Image

Oncolytic Virus Therapy Global Market Insights 2023, Analysis and Forecast to 2028, by Manufacturers, Regions, Technology, Application, Product Type

  • Report
  • 101 Pages
  • Global
From
Oncolytic Virus Therapy Market - Global Industry Size, Share, Trends, Opportunity, & Forecast 2018-2028 - Product Image

Oncolytic Virus Therapy Market - Global Industry Size, Share, Trends, Opportunity, & Forecast 2018-2028

  • Report
  • 181 Pages
  • Global
From
Oncolytic Virus Cancer Therapy - Pipeline Insight, 2024 - Product Image

Oncolytic Virus Cancer Therapy - Pipeline Insight, 2024

  • Clinical Trials
  • 280 Pages
  • Global
From

About the Oncolytic Virus Drug Market

The Oncolytic Virus Drug market is a subset of the Oncology Drugs market, which focuses on treatments for cancer. Oncolytic virus drugs are a type of biologic therapy that uses viruses to target and destroy cancer cells. These drugs are designed to selectively infect and kill cancer cells while leaving healthy cells unharmed. They can be used alone or in combination with other treatments such as chemotherapy or radiation therapy. Oncolytic virus drugs have the potential to improve the efficacy of existing treatments and reduce the side effects associated with them. Some companies in the Oncolytic Virus Drug market include Amgen, Merck, Pfizer, and Novartis. These companies are actively researching and developing new oncolytic virus drugs to treat a variety of cancers. Show Less Read more

Copyright © 2002-2024 Research and Markets. All Rights Reserved.